Application of Escherichia coli and gene engineering bacteria thereof in preparing anti-liver-cancer solid tumor drugs

Abstract

The invention discloses a new application of Escherichia coli and gene engineering bacteria thereof, namely, the application in preparing anti-liver-cancer solid tumor drugs. The application is as follows: an injection is prepared by the Escherichia coli or the gene engineering bacteria thereof or the mixture of the Escherichia coli and the gene engineering bacteria thereof, and is directly inoculated to a tumor tissue of the liver cancer solid tumor so as to the treat liver cancer solid tumor. The invention has the advantage that the invention is beneficial to fulling exhibiting the dual anti-tumor effect and the synergistic anti-tumor effect of the bacteria and cytokines. Simultaneously, the invention is beneficial to reducing or avoiding adverse reactions of the systemic application ofbacteria and cytokines, and the method is simple and easy. The invention provides a more ideal anti-liver-cancer solid tumor drug.

Description

technical field [0001] The invention relates to the use of Escherichia coli and its genetically engineered bacteria, in particular to the application of Escherichia coli and its genetically engineered bacteria in the preparation of anti-liver solid tumor drugs. Background technique [0002] The incidence of tumors is high, among which solid tumors are the main ones. Liver cancer, as a high-incidence malignant tumor, is known as the "king of cancer" because of its high degree of malignancy and poor prognosis. [1] , ranking second in the mortality rate of malignant tumors [2] . At present, the clinical treatment effect of solid tumors such as liver cancer is not ideal, the main reason is that there are few innovative drugs and treatment methods at the source, the treatment is poorly targeted, and there are also problems such as high recurrence and metastasis rates. Therefore, it is of great significance to research and develop new technologies and methods for the treatment ...

AI Technical Summary

Problems solved by technology

(3) Bacterial toxic products destroy the tumor microenvironment

The biggest problem at present is: Bifidobacterium is used as a carrier, and its plasmids are relatively few, and it is difficult to extract. Among the 24 types, only 5 types of plasmids are found. Not suitable for vector construction [15，16] , becoming the bottleneck of its application in gene therapy

However, commercially available cytokines contain impurities, and repeated injections of large doses of cytokines to tumor patients or animal models often cause many toxic and side effects, which has become the biggest obstacle to its clinical application